SA-302

N/A

Report date: 2025/04/18 10:41:18

Base Information

Drug NameSA-302
Drug Alias NameSA-302
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > TCR therapy
Mechanisms of ActionV-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog modulators
TargetsGTPase KRas
Therapy Area/IndicationsLung NeoplasmsPancreatic NeoplasmsColorectal Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaPreclinical
Originator CompaniesWuhan Sian Biotechnology Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesWuhan Sian Biotechnology Co Ltd
Inactive CompaniesN/A
Active IndicationsLung NeoplasmsPancreatic NeoplasmsColorectal Neoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A